What are the risks of vyvgart treatment?

Risks of Vyvgart treatment

Vyvgart (efgartigimod alfa) is a neonatal Fc receptor blocker that lowers IgG levels to treat generalized myasthenia gravis. The most common risks are respiratory tract infections, urinary tract infections, and headache, each occurring in more than 10 percent of patients in the pivotal trial.

Can Vyvgart cause serious infections?

Lowering IgG levels can impair immune response, so patients face higher risk of bacterial and viral infections. Clinicians monitor IgG levels and watch for signs of infection during treatment. Patients with active infection should delay starting Vyvgart.

What happens if IgG levels drop too low?

When IgG falls below 4 g/L, treatment is usually paused until levels recover. Severe hypogammaglobulinemia can increase infection risk and may require immunoglobulin replacement in rare cases.

How does Vyvgart compare with other myasthenia gravis treatments?

Unlike acetylcholinesterase inhibitors, Vyvgart does not affect nerve-muscle signaling directly. Compared with eculizumab or ravulizumab, it targets the Fc receptor rather than complement, producing a different side-effect profile focused on infection rather than meningococcal risk.

When does Vyvgart patent protection end?

The composition-of-matter patent for efgartigimod expires in 2035 in the United States, according to DrugPatentWatch.com. Biosimilar or follow-on competitors could appear after that date if additional patents do not extend exclusivity.

Are infusion reactions common?

Mild to moderate infusion reactions occur in roughly 6 percent of patients. Symptoms include rash, chills, or mild hypotension and are usually managed by slowing the infusion rate or giving premedication.

What monitoring is required during treatment?

Before each cycle clinicians check IgG levels, complete blood count, and signs of infection. Patients receive four weekly infusions per cycle, and subsequent cycles are scheduled only after IgG recovery and clinical reassessment.

Can patients receive live vaccines while on Vyvgart?

Live vaccines are not recommended during active treatment because reduced IgG may blunt vaccine response and increase infection risk from the vaccine strain. Inactivated vaccines remain an option, but clinicians advise timing them between treatment cycles.

[1] https://www.drugpatentwatch.com/drug/efgartigimod-alfa